iosBio
iosBio is a UK-based biotechnology company developing thermostable, orally delivered vaccines. The company focuses on formulation and delivery of non-replicating viral vector vaccines in oral capsule form, enhanced antigen presentation, and AI-assisted antigen design to accelerate vaccine discovery and enable mucosal and systemic immunity. Its lead program is an oral Epstein‑Barr Virus (EBV) vaccine candidate being advanced toward clinical testing.
Industries
Nr. of Employees
small (1-50)
Patents
Excipients for stabilising viral particles, polypeptides or biological material
US-10716859-B2
View Details
Excipients for stabilising viral particles, polypeptides or biological material
US-10716859-B2
View DetailsProducts
Oral thermostable EBV vaccine candidate (lead program)
A first‑in‑class, orally administered, thermostable vaccine candidate targeting Epstein‑Barr Virus, reported to induce strong antibody responses in preclinical studies and being prepared for Phase 1 clinical testing.
Oral thermostable EBV vaccine candidate (lead program)
A first‑in‑class, orally administered, thermostable vaccine candidate targeting Epstein‑Barr Virus, reported to induce strong antibody responses in preclinical studies and being prepared for Phase 1 clinical testing.
Services
Computational antigen screening and structural optimization to improve immunogenicity, stability and manufacturability.
Formulation and oral capsule delivery service for thermally-stabilised viral vector vaccines designed to enable room-temperature distribution and self-administration.
Engineering of antigen presentation on host cells to increase surface density and persistence to boost immune responses.
Computational antigen screening and structural optimization to improve immunogenicity, stability and manufacturability.
Formulation and oral capsule delivery service for thermally-stabilised viral vector vaccines designed to enable room-temperature distribution and self-administration.
Engineering of antigen presentation on host cells to increase surface density and persistence to boost immune responses.
Expertise Areas
- Oral vaccine development
- Thermostable vaccine formulation
- Viral vector engineering
- Antigen design using AI
Key Technologies
- Thermostable oral capsule vaccine delivery
- Non-replicating adenoviral vector engineering
- Antigen surface display enhancement
- AI-driven antigen design (in silico optimization)
News & Updates
Signed an exclusive worldwide licensing agreement granting a partner rights to the company’s oral vaccine thermal stabilization platform for a COVID‑19 vaccine program (press release dated January 12, 2021).
Received a £288,000 grant from the Department of Health and Social Care's UK Vaccine Network (delivered by Innovate UK) to support development of an oral Nipah virus vaccine using the thermostable oral platform (press release dated February 23, 2022).
Announcement of appointment of Ben Warriner as Chief Financial Officer effective 6 April 2022.
Announcement of appointment of Dr Craig Laferrière as Chief Development Officer effective 19 May 2022.
Public statement of seeking £12–30 million in Series B funding to advance the lead oral EBV vaccine through Phase 1/2 and scale operations.
Signed an exclusive worldwide licensing agreement granting a partner rights to the company’s oral vaccine thermal stabilization platform for a COVID‑19 vaccine program (press release dated January 12, 2021).
Received a £288,000 grant from the Department of Health and Social Care's UK Vaccine Network (delivered by Innovate UK) to support development of an oral Nipah virus vaccine using the thermostable oral platform (press release dated February 23, 2022).
Announcement of appointment of Ben Warriner as Chief Financial Officer effective 6 April 2022.
Announcement of appointment of Dr Craig Laferrière as Chief Development Officer effective 19 May 2022.
Public statement of seeking £12–30 million in Series B funding to advance the lead oral EBV vaccine through Phase 1/2 and scale operations.